Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer

Status unconfirmed · Phase 2

Conditions studied: Head and Neck Cancer

In brief

RATIONALE: Inserting the gene for p53 into a person's tumor may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have recurrent head and neck cancer.

Key facts

Study ID

NCT00003257

Run by

Aventis Pharmaceuticals

People needed

39

Starts

1998-01-01

Last updated by the study team

2013-12-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Sidney Kimmel Cancer Center — San Diego, California, United States
• University of Colorado Cancer Center — Denver, Colorado, United States
• University of Connecticut School of Medicine — Farmington, Connecticut, United States
• Clinical Sciences Building — Chicago, Illinois, United States
• University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Tulane University School of Medicine — New Orleans, Louisiana, United States
• Marlene & Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
• Albert Einstein Comprehensive Cancer Center — The Bronx, New York, United States
• Simmons Cancer Center - Dallas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.